Cantargia AB (publ) has completed a directed share issue of approximately SEK 410 million before transaction related costs.

Investors in the directed share issue are a wide range of Swedish and international investors including new investors such as Swedbank Robur, HBM Healthcare Investments, Granite Point Capital and Unionen as well as current shareholders such as Fjärde AP-fonden, Alecta, Första AP-fonden and Handelsbanken Fonder.

Cantargia is a biotechnology company that develops antibody-based treatments for life-threatening diseases.

Carnegie Investment Bank AB and Zonda Partners AB acted as Joint Bookrunners in connection with the directed share issue and Baker McKenzie acted as legal counsel to the Joint Bookrunners. Baker McKenzie's team consisted of Joakim Falkner, Henric Roth, Ian Gulam from the Stockholm office and Megan Schellinger from the London office.
Explore Our Newsroom